医药制造业

Search documents
新 和 成出资50000万元成立浙江新和成控股有限公司,持股100%
Jin Rong Jie· 2025-07-04 01:18
Group 1 - Zhejiang Xinhengcheng Co., Ltd. has invested 500 million RMB to establish Zhejiang Xinhengcheng Holdings Co., Ltd., holding 100% of the shares [1] - Zhejiang Xinhengcheng Holdings Co., Ltd. was established on April 15, 2025, with a registered capital of 500 million RMB and is located in Hangzhou [2] - The company operates in the pharmaceutical manufacturing industry and has various licensed projects including drug wholesale, retail, import and export, and sales of controlled chemicals [2] Group 2 - The company is involved in a wide range of activities including engineering management services, property management, technology development, and various types of chemical product sales [2] - Specific areas of research and development include bio-feed, industrial enzyme preparations, and new organic active materials [2] - The company also engages in the sale of health products, disinfectants, and pet food, among other items [2]
江苏禾莲清源生物技术有限公司成立,注册资本1000万人民币
Sou Hu Cai Jing· 2025-07-03 06:11
经营范围含许可项目:第二类医疗器械生产;食品销售(依法须经批准的项目,经相关部门批准后方可 开展经营活动,具体经营项目以审批结果为准)技术服务、技术开发、技术咨询、技术交流、技术转 让、技术推广;工业酶制剂研发;生物基材料技术研发;日用化学产品销售;生物化工产品技术研发; 生物基材料制造;第二类医疗器械销售;食品互联网销售(仅销售预包装食品);保健食品(预包装) 销售;特殊医学用途配方食品销售;科技中介服务;宠物食品及用品批发;新材料技术研发;生物饲料 研发;健康咨询服务(不含诊疗服务);企业管理咨询;自有资金投资的资产管理服务;以自有资金从 事投资活动;货物进出口;技术进出口;进出口代理(除依法须经批准的项目外,凭营业执照依法自主 开展经营活动) 企业名称江苏禾莲清源生物技术有限公司法定代表人王栋梁注册资本1000万人民币国标行业制造业>医 药制造业>化学药品制剂制造地址江苏省南通市开发区新东路5号内2幢-24062号企业类型其他有限责任 公司营业期限2025-7-1至无固定期限登记机关南通市经济技术开发区行政审批局 序号股东名称持股比例1江苏鸿信半导体科技有限公司70%2南通追日润信息技术有限公司30% ...
6月PMI释放双重信号:制造业景气水平持续改善 小企业承压待政策加码
Jing Ji Guan Cha Wang· 2025-06-30 12:59
Group 1 - The manufacturing PMI for June is reported at 49.7%, indicating a slight improvement from the previous value of 49.5%, suggesting a continued recovery in manufacturing activity [1] - The construction business activity index rose to 52.8% from 51%, while the services business activity index decreased to 50.1%, down by 0.1 percentage points from the previous month [1] - The production index and new orders index in manufacturing are both in the expansion zone, with marginal increases of 0.3 and 0.4 percentage points to 51% and 50.2%, respectively [2] Group 2 - The internal demand index increased by 0.4 percentage points to 50.6%, outpacing the new export orders index, which rose by 0.2 percentage points to 47.7% [2] - High-frequency indicators show that the year-on-year growth rate of foreign trade cargo volume narrowed from -3.8% to -3.5%, indicating a continued weakening in export strength [2] - The PMI data indicates a divergence in performance among enterprises, with large and medium-sized enterprises seeing increases in PMI, while small enterprises experienced a decline to 47.3%, the lowest since September 2024 [3] Group 3 - The manufacturing sector faces downward pressure due to a potential weakening in export chain production as the equipment renewal cycle declines [3] - Recent policies aimed at boosting domestic demand, including a 500 billion yuan service consumption relending initiative, are expected to support service consumption and infrastructure investment [3] - The PMI improvements in June were more pronounced in industries such as petroleum processing, pharmaceutical manufacturing, and chemical manufacturing, while sectors like electrical machinery and textiles saw significant declines [3]
冲击IPO!国产可吸收外科缝线企业
思宇MedTech· 2025-06-27 09:07
思宇年度活动回顾: 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 | 首届全球医美科技大会 即将召开: 2025年7月17日,第二届全球医疗科技大会 2025年9月3-5日,第三届全球手术机器人大会 2025年6月,海南证监局正式受理 百迈科北交所上市辅导备案材料 ,同意辅导备案, 百迈科正式开启IPO 。 | | | | 辅导对象 | 海南百迈科医疗科技股份有限公司 | | | | --- | --- | --- | --- | | 成立日期 | 2007-06-01 | | | | 注册资本 | 4,065.00万元 | 法定代表人 | 杨顶建 | | 注册地址 | 海南省定安县定城镇见龙社区环城南三环路18号 | | | | 控股股东 及持股比 | 控股股东为海南迈迪科医药控股有限公司,持股比例为 48.35% | | | | 倒 | | | | | 行业分类 | C27 医药制造业 | 在其他交易场 所(申请)挂 脾或上市的情 | 新三板挂牌(股票简 称:自迈科;股票代 码: 874640) | | | | 况 | | | 各 注 | 无 | | | # 财务数据 2024年,百迈科 ...
“互换大气污染物总量指标”为区域高质量发展和高水平保护注入新动能
Zhong Guo Huan Jing Bao· 2025-06-27 00:14
Core Viewpoint - The recent agreement between Chengdu's Wenjiang District and Qingbaijiang District to exchange air pollutant emission quotas is a strategic move to optimize environmental capacity while supporting economic development and improving air quality [1][2]. Group 1: Agreement Details - Wenjiang District exchanged 90 tons of volatile organic compounds (VOCs) for 60 tons of nitrogen oxides (NOx) from Qingbaijiang District, facilitating the efficient matching of emission quotas with construction projects [1]. - The exchanged NOx quotas will support major projects with a total investment exceeding 3 billion yuan, while the VOC quotas will back projects totaling approximately 15 billion yuan [1]. Group 2: Mechanism and Benefits - The new "bulk exchange" mechanism, introduced by the recent regulations, allows districts meeting specific air quality standards to optimize their emission quotas based on actual development needs [1][2]. - This mechanism simplifies the process of securing necessary emission quotas, significantly accelerating the implementation of air-related construction projects [2]. Group 3: Regional Implications - The practice in Chengdu serves as a model for other regions facing environmental capacity constraints, encouraging them to explore similar quota exchange systems [2]. - Effective implementation of the exchange mechanism requires thorough preliminary research to assess the impact on local air quality, ensuring compliance with air quality standards [2][3]. Group 4: Governance and Oversight - Strengthening policy guidance and clear communication regarding the exchange process is essential for the successful operation of the quota exchange mechanism [3]. - There is a need for comprehensive monitoring and regulation to prevent fraudulent activities during the exchange process, ensuring the integrity of environmental quality improvements [3]. Group 5: Economic and Environmental Value - The quota exchange mechanism highlights the dual value of emission quotas, emphasizing the importance of proactive emission reduction efforts even in areas with surplus environmental capacity [3]. - This approach not only meets local development needs but also opens new economic growth opportunities through market transactions and regional exchanges [3].
又新受理19家IPO!今年至今获受理共80家
梧桐树下V· 2025-06-25 11:15
文/梧桐数据中心 6月23日至6月24日,深、北交易所又新受理了19家IPO。其中深交所主板新受理1家:福恩股份,创业板新受理4家:贝特利、联亚药业、欣兴 工具、高特电子;北交所新受理14家:南方乳业、中健康桥、康美特、海昌智能、德硕科技、弥富科技、新纳科技、中德科技、斯瑞达、北 方实验、欧伦电气、广泰真空、天康制药、传美讯。 截至6月24日,2025年沪、深、北三大交易所共受理了80家IPO项目,其中上交所受理了14家、深交所受理了17家、北交所受理了49家。 一、杭州福恩股份有限公司深主板IPO,6月24日获受理 公司前身有限公司成立于1997年1月22日,2023年9月1日整体变更为股份公司。公司目前注册资本17,500万元。 (一)主营业务 公司是一家以可持续发展为核心的全球生态环保面料供应商,以生态环保面料的研发、生产和销售作为主营业务。公司的主要产品为生态环 保面料,以再生面料为主。 (二)控股股东、实际控制人 湃亚控股持有公司6,400万股股份,持股比例为36.57%,为公司控股股东。公司的实际控制人为王内利、王学林和王恩伟,王内利、王学林系 夫妻关系,王内利、王恩伟系父女关系。王内利、王学林和 ...
华海药业: 浙商证券股份有限公司关于浙江华海药业股份有限公司公开发行可转换公司债券受托管理事务报告(2024年度)
Zheng Quan Zhi Xing· 2025-06-24 16:50
浙江华海药业股份有限公司公开发行可转换公司债券 2025 年跟踪评级报告 预计将于 2025 年 6 月 30 日前出具。 浙商证券股份有限公司 关于 浙江华海药业股份有限公司 公开发行可转换公司债券 受托管理事务报告 (2024 年度) 债券代码 债券简称 债券受托管理人 (注册地址:浙江省杭州市五星路 201 号) 二〇二五年六月 重要声明 浙商证券股份有限公司(以下简称"浙商证券""受托管理人")根据《中华 人民共和国证券法》《公司债券发行与交易管理办法》《公司债券受托管理人 执业行为准则》等法律法规、自律规则等规范性文件要求,以及受托管理的浙 江华海药业股份有限公司(以下简称"华海药业""发行人"或"公司")存续期公 司债券募集说明书、受托管理协议等债券发行信息披露文件约定要求进行编 制。 浙商证券编制本报告的内容及信息均来源于发行人对外公布的《浙江华海 药业股份有限公司 2024 年年度报告》及相关公开信息披露文件、第三方中介机 构出具的专业意见以及发行人向浙商证券提供的其他材料。 本报告不构成对投资者进行或不进行某项行为的推荐意见,投资者应对相 关事宜作出独立判断,而不应将本报告中的任何内容据以作 ...
百迈科启动IPO辅导:董事长杨顶建控股61%,曾担任兰州大学教师
Sou Hu Cai Jing· 2025-06-24 02:51
Company Overview - Hainan Baimaike Medical Technology Co., Ltd. (Baimaike) is a high-tech enterprise established on June 1, 2007, specializing in the research, production, and sales of surgical medical devices and peptide pharmaceutical equipment [1] - The company is planning to go public on the Beijing Stock Exchange with the guidance of Changcheng Securities [1] Financial Performance - In 2024, Baimaike achieved an operating income of 185 million yuan, representing a year-on-year growth of 6.27% [2][3] - The net profit attributable to shareholders decreased by 1.41% to approximately 69.19 million yuan [2][3] - The gross profit margin improved to 78.8%, up from 75.88% in the previous year [2][3] Shareholding Structure - The controlling shareholder is Hainan Maidike Pharmaceutical Holdings Co., Ltd., holding 48.35% of the shares [1][3] - Yang Dingjian, the actual controller, directly holds 2.98 million shares (7.33% of total shares) and indirectly controls 60.99% of the voting rights through various entities [4][6] Leadership Background - Yang Dingjian, born in October 1972, holds a Ph.D. in Biochemistry and Molecular Biology from Lanzhou University and has extensive experience in the pharmaceutical industry [6][7] - He has held various leadership positions, including General Manager of Hainan Zhonghe Pharmaceutical Co., Ltd. and Chairman of Baimaike since June 2022 [6][7]
6月23日午间公告一览:温州宏丰控股子公司获得实用新型专利证书
news flash· 2025-06-23 04:07
温州宏丰(300283)公告,控股子公司浙江宏丰铜箔有限公司于近日收到国家知识产权局颁发的1项实 用新型专利证书。专利名称为"一种生箔机边部抛光装置",专利号为"ZL202422197490.0",专利申请日 为2024年9月9日,授权公告日为2025年6月20日,授权公告号为"CN223000261U"。该专利的专利权期限 为十年,自申请日起算。上述专利的取得不会对公司短期业绩产生重大影响,但有利于发挥公司及子公 司自主知识产权优势,形成持续创新机制,提升公司及子公司核心竞争力。 一品红(300723)公告,全资子公司获得注射用唑来膦酸浓溶液注册证书。注射用唑来膦酸浓溶液是国 家医保乙类产品。公司获批的注射用唑来膦酸浓溶液是以化学药品4类申报注册,视同通过一致性评 价。 ...
智飞生物(300122)6月20日主力资金净流入3855.32万元
Sou Hu Cai Jing· 2025-06-23 00:33
Financial Performance - As of June 20, 2025, Zhifei Biological reported a closing price of 19.02 yuan, with a slight increase of 0.42% [1] - The total operating revenue for the first quarter of 2025 was 2.374 billion yuan, representing a year-on-year decrease of 79.16% [1] - The net profit attributable to shareholders was approximately 305.14 million yuan, down 120.93% year-on-year [1] - The company's current ratio is 2.298, quick ratio is 1.029, and debt-to-asset ratio stands at 36.85% [1] Market Activity - The trading volume was 222,300 hands, with a total transaction amount of 425 million yuan [1] - The net inflow of main funds was 38.55 million yuan, accounting for 9.06% of the transaction amount [1] - Large orders saw a net inflow of 44.10 million yuan, while small orders experienced a net outflow of 42.67 million yuan [1] Company Overview - Zhifei Biological, established in 1995, is located in Chongqing and primarily engages in the pharmaceutical manufacturing industry [2] - The company has a registered capital of approximately 2.39 billion yuan and a paid-in capital of 400 million yuan [1] - Zhifei Biological has made investments in 9 companies and participated in 1,149 bidding projects [2]